Researchers discuss the psychedelic renaissance on 'What Happens Next?'
Attitudes towards psychoactive drugs for the treatment of mental health are changing, and for good reason – it’s hard to disagree with the evidence of the therapeutic benefits. Compelling studies are being conducted around the world, several of them here at Monash. And it won’t be long until you see the results of these studies for yourself – experts suggest health care providers could begin prescribing psychedelic drugs for PTSD patients as soon as 2023.
In this episode of What Happens Next?, Dr Susan Carland talks to Dr Paul Liknaitzky, the principal investigator on a number of Australia’s first clinical psychedelic trials. She’s also joined by Dr Meaghan O’Donnell, head of research at Phoenix Australia, the centre for posttraumatic mental health, and professor in the Department of Psychiatry at the University of Melbourne.